INmune Bio (INMB) Competitor Comparison
We are evaluating the key criteria listed to compare INmune Bio (INMB) against its competitors in the Biotechnology industry.
Market Capitalization
219 / 368Gross Profits
136 / 278Total Revenue
269 / 300EBITDA
0 / 337Free Cashflow
65 / 352Quick Ratio
259 / 357Earnings per Share
214 / 359Dividend yield
0 / 6Total Cash
271 / 358Performance 3 years
180 / 368Performance 5 years
113 / 368Performance 10 years
127 / 368Linearity 3 years
110 / 368Linearity 5 years
39 / 368Linearity 10 years
26 / 368Total Rank
158 / 368Dividend Rank
163 / 368Valuation Rank
63 / 368Piotroski Rank
132 / 368Muliplier Rank
366 / 368Valuation Rank - INMB ranking 63 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.